Assay | Study (reference) | Year | N | Country incidence | Population | Target condition | Setting | Sensitivity (95% CI) | Specificity (95% CI) | Gold standard |
QFT-GIT | Prospective head-to-head study comparing 2 commercial interferon gamma release assays for the diagnosis of tuberculous uveitis17 | 2014 | 120 | Singapore (mid TB incidence) | Patients with uveitis | TB uveitis | Eye hospital | 0.64 (0.60 to 0.69) | 0.995 (0.988 to 0.999) | Not specified. |
T-SPOT.TB | Interferon-gamma release assay as a diagnostic test for tuberculosis-associated uveitis34 | 2012 | 138 | Singapore (mid TB incidence) | Patients with uveitis | TB uveitis | Eye hospital | 0.36 | 0.75 | Not specified. |
Interferon γ release assay for the diagnosis of uveitis associated with tuberculosis: a Bayesian evaluation in the absence of a gold standard67 | 2013 | 191 | Singapore (mid TB incidence) | Patients with uveitis | TB uveitis | Eye hospital | 0.50 (0.33 to 0.67) | 0.91 (0.88 to 0.93) | None, a Bayesian latent class model used instead. | |
Prospective head-to-head study comparing 2 commercial interferon gamma release assays for the diagnosis of tuberculous uveitis17 | 2014 | 120 | Singapore (mid TB incidence) | Patients with uveitis | TB uveitis | Eye hospital | 0.67 (0.60 to 0.74) | 0.91 (0.88 to 0.93) | Not specified. | |
Evaluation of the accuracy of T-SPOT.TB for the diagnosis of ocular tuberculosis in a BCG-vaccinated, non-endemic population36 | 2017 | 40 | Chile (low TB incidence) | Patients with uveitis | TB uveitis | Tertiary referral centre | 0.80 (0.53 to 0.94) | 0.85 (0.62 to 0.96) | Positive TST with intraocular inflammation and positive response to ATT. |
ATT, antituberculous treatment; IGRAs, interferon gamma release assays; QFT-GIT, QuantiFERON-TB Gold In-Tube assay; TB, tuberculosis; TST, tuberculin skin test.